Scientific Program

9th International Conference on

LEUKEMIA AND HEMATOLOGIC ONCOLOGY

October 05-06, 2017   London, UK
Keynote Forum

09:45-10:30
Title: Targeting MCL1-dependant cancers by CDK9 inhibition
David J. Bearss, Tolero Pharmaceuticals Inc., USA

10:30-11:15
Title: Targeting novel kinases in hematological malignancies
Steven L. Warner, Tolero Pharmaceuticals Inc., USA

Networking and Refreshments Break @ Breakout Areas 11:15-11:30

Special session

11:30-12:15
Title: Extension of 2016 World Health Organization (WHO) classification into a new set of clinical, laboratory, molecular, and pathological criteria for the diagnosis of myeloproliferative neoplasms: from Dameshek to Vainchenker, Green and Kralovics
Jan Jacques Michiels, Goodheart Institute, Netherlands

Symposium

12:15-13:00
Title: Variations in ALL responses to Daunorubicin exist independently of genetic variation in the ATM gene.
Hussain M Al-Aamri, Latrobe University, Australia

Lunch Break @ RBG 13:00-14:00

Sessions: Leukemia | Hematologic Oncology | Blood Disorders and Blood Oncology
Session Chair: Omnia K. ElGebaly, Cairo University, Egypt

Session Introduction

14:00-14:25
Title: Screening and identification of microRNA related with prognosis in patients with extranodal NK/T lymphomas
Feng Xiaoli, China

14:25-14:50
Title: Modelling human point mutation diseases in Xenopus tropicalis with a modified CRISPR/Cas9 system
Yonglong Chen, Southern University of Science and Technology, China

14:50-15:15
Title: Vitamin D gene polymorphism in multiple myeloma, chronic lymphocytic leukemia and chronic myeloid leukemia
Anil Tombak, Mersin University Medical Faculty, Turkey

15:15-15:40
Title: mTOR expression in acute lymphoblastic leukemia: Possible contribution of mTOR in predicting response to induction chemotherapy
Asheema Khanna, National Institute of Pathology, India

Networking and Refreshments Break @ Breakout Areas 15:40-15:55

15:55-16:20
Title: Translation of WHO into improved clinical, laboratory, molecular and pathological (CLMP) criteria for the diagnoses of JAK2 trilinear myeloproliferative neoplasm, MPL thrombocytethyema and CALR thrombocytethyema and myelofibrosis: From Dameshek to Vainchenker Green, Kralovics and Skoda
Jan Jacques Michiels, Goodheart Institute, Netherlands

16:20-16:45
Title: Prognostic significance of progenitor cell markers CD34/CD38 expression in acute myeloid leukaemia egyptian patients
Omnia K. ElGebaly, Cairo University, Egypt

Panel Discussion
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00-10:45</td>
<td><strong>Keynote Forum</strong>&lt;br&gt;<strong>Title:</strong> Sticky platelet syndrome and MPN disease burden in JAK2 Thrombocythemia and Polycythemia Vera, and in JAK2, MPL and CALR Thrombocythemias: Implications for novel non-leukemogenic treatment options in prefibrotic Myeloproliferative Neoplasms anno 2018&lt;br&gt;<strong>Jan Jacques Michiels,</strong> Goodheart Institute, Netherlands</td>
</tr>
<tr>
<td>10:45:11:15</td>
<td><strong>Special Session</strong>&lt;br&gt;<strong>Title:</strong> Clinicopathological study of coagulation profile in non-haematological malignancies&lt;br&gt;<strong>Sushma belurkar,</strong> Manipal University, India</td>
</tr>
<tr>
<td>11:15-11:30</td>
<td>Networking and Refreshments Break @Breakout Areas</td>
</tr>
</tbody>
</table>
| 11:30-11:55  | **Session:** Pediatric hematologist/oncologist | Leukemia Risk factors | Hemato Immunology &Stem Cell Research | Leukemia Immunology<br>**Session Chair:** Steven L. Warner, Tolero Pharmaceuticals Inc., USA
|              | **Title:** Glutathione is key to the synergistic enhancement of doxorubicin and etoposide by polyphenols in leukaemia cell lines.<br>**Mahbub Amani A,** Umm Al Qura University, Saudi Arabia |
|              | **Title:** Role of ROS, DNA repair, and apoptosis to daunorubicin chemotherapy of Acute lymphoblastic leukemia<br>**Hussain M Al-Aamri,** Latrobe University, Australia |
|              | **Title:** S100A4 protein regulates cell trafficking in B-Cell Lymphomas.<br>**Zamzam Amutairi,** United Kingdom |
| 12:45-13:30  | Lunch Break@ RBG 12:45-13:30                                                                    |
| 13:30-13:55  | **Title:** Dietary polyphenols influence antimetabolite agents: Methotrexate, 6-Mercaptopurine and 5-Fluorouracil in leukemia cell lines.<br>**Mahbub Amani A,** Umm Al Qura University, Saudi Arabia |
|              | **Title:** Acute myeloid leukemia detection in WBC cell based on ICA feature extraction<br>**Jasvir Kaur,** IK Gujral Punjab Technical University, India |
|              | **Title:** New opportunities in hematologic malignancy treatment: therapeutic application of PI3K inhibitors<br>**Ava Safaroghli-Azar,** Hahid Beheshti University of medical sciences, Iran |
|              | **Title:** The addition of immunotherapy to chemotherapy in the treatment of diffuse large B-cell lymphoma: Retrospective comparison of CHOP versus R-CHOP regimens in Egyptian patients.<br>**Usama Elnagar,** Saudi Arabia |
|              | **Title:** Demographics and symptom burden of philadelphia negative myeloproliferative neoplasms in Sudan<br>**Sahar,** University of Medical Science and Technology, Sudan |
|              | **Title:** Effectiveness of P.N.D in prevention of major beta thalassemia in south of Iran.<br>**Abdolreza Afrasiabi,** Shiraz University of Medical Sciences, Iran |
| 16:00-16:15  | Networking and Refreshments Break 16:00-16:15 @ Breakout Areas                                 |
|              | **Panel Discussion**                                                                            |
|              | **Awards & Closing Ceremony**                                                                    |